Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (Weighted Average): 2015-2025

Historic Shares Outstanding (Weighted Average) for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $9.9 million.

  • Aytu Biopharma's Shares Outstanding (Weighted Average) rose 61.20% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 61.20%. This contributed to the annual value of $6.2 million for FY2025, which is 10.81% up from last year.
  • Per Aytu Biopharma's latest filing, its Shares Outstanding (Weighted Average) stood at $9.9 million for Q3 2025, which was up 60.64% from $6.2 million recorded in Q2 2025.
  • Aytu Biopharma's Shares Outstanding (Weighted Average)'s 5-year high stood at $9.9 million during Q3 2025, with a 5-year trough of $894,145 in Q1 2021.
  • Over the past 3 years, Aytu Biopharma's median Shares Outstanding (Weighted Average) value was $5.6 million (recorded in 2024), while the average stood at $5.7 million.
  • Per our database at Business Quant, Aytu Biopharma's Shares Outstanding (Weighted Average) soared by 676.91% in 2021 and then fell by 10.45% in 2024.
  • Over the past 5 years, Aytu Biopharma's Shares Outstanding (Weighted Average) (MRQ) stood at $1.4 million in 2021, then surged by 121.79% to $3.1 million in 2022, then skyrocketed by 78.36% to $5.6 million in 2023, then grew by 10.45% to $6.1 million in 2024, then surged by 61.19% to $9.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $9.9 million in Q3 2025, compared to $6.2 million in Q2 2025 and $6.2 million in Q1 2025.